Central serotonergic stimulation of aldosterone secretion

Area of Science:

• Endocrinology
• Neuroendocrinology
• Human Physiology

Background:

• Serotonin is known to stimulate aldosterone secretion in vitro and in vivo.
• Serotonin antagonism reduces plasma aldosterone in idiopathic aldosteronism.
• The role of serotonin precursors in aldosterone regulation requires further investigation.

Purpose of the Study:

• To evaluate the effect of 5-hydroxytryptophan (5HTP) on human aldosterone secretion.
• To determine if 5HTP's stimulatory effects on aldosterone are mediated centrally.
• To explore the potential role of 5HTP in idiopathic aldosteronism.

Main Methods:

• Oral 5HTP (200 mg) administration to normal volunteers pretreated with dexamethasone.
• Peripheral 5HTP decarboxylation inhibition using carboxydopa.
• Measurement of plasma aldosterone, renin activity, potassium, ACTH, 5HTP, and serotonin levels.
• Assessment of 5HTP effects in patients with idiopathic aldosteronism and aldosterone-producing adenoma.
• In vitro incubation of adrenal glomerulosa cells with serotonin and 5HTP.

Main Results:

• Single oral 5HTP dose significantly increased plasma aldosterone levels in normal volunteers.
• Carboxydopa pretreatment enhanced 5HTP's stimulatory effect on aldosterone, suggesting central mediation.
• No significant changes in renin activity, potassium, or ACTH accompanied aldosterone increase.
• 5HTP increased aldosterone in idiopathic aldosteronism patients, but responses varied in adenoma patients.
• Serotonin stimulated aldosterone in vitro, while 5HTP did not.

Conclusions:

• Central serotonergic pathways are implicated in 5HTP-induced aldosterone stimulation.
• This mechanism may contribute to aldosterone hypersecretion in idiopathic aldosteronism.
• 5HTP acts centrally to influence aldosterone, distinct from direct adrenal effects.